THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive echotherapy, announces todaythe launch of SONOVEIN® HD. This new system combines the first and only extracorporeal therapeutic ultrasound solution with leading-edge imaging capabilities from SuperSonic Imagine (recently acquired by Hologic), made in Aix-en-Provence, France.
Less than 3 years after unveiling the first SONOVEIN®, Theraclion is launching its CE-marked third-generation platform, SONOVEIN® HD. This new edition is the result of Theraclion research team’s technical developments and the integration of best-in-class high-definition imaging technologies MACH30 10-12Mhz imaging system.
“High-end visualization technology is key to an optimal workflow, efficiency, and safety. The launch of SONOVEIN® HD is a transforming event for Theraclion”, commented David Caumartin, CEO of Theraclion.
“SONOVEIN® HD allowed me to complete the fastest vein treatment I have ever done. It speeds up the process, avoiding repositioning and increasing confidence. It truly is an innovation for vascular doctors and will benefit patients,” explains Dr Guillaume Stalnikiewicz, France, renowned vascular doctor and one of the SONOVEIN global pioneers.
A few days after the treatment of the first patients in the US, the SONOVEIN® HD release represents the ultimate technological milestone in Theraclion’s ambition to revolutionize varicose vein treatment. Theraclion is on track to transform this large global market. Varicose veins affect an estimated 30% of the world’s adult population and require about 5 million medical procedures annually.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
